ABSTRACT
Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a significant milestone in cancer immunotherapy. However, the efficacy of CAR-T therapy for the treatment of acute myeloid leukemia (AML) is poor. The challenges associated with the application of CAR-T therapy for the clinical treatment of AML include, but are not limited to, nonspecific distribution of AML therapeutic targets, difficulties in the production of CAR-T cells, AML blast cell heterogeneity, the immunosuppressive microenvironment in AML, and treatment-related adverse events. In this review, we summarize the recent findings regarding various therapeutic targets for AML (CD33, CD123, CLL1, CD7, etc.) and the results of the latest clinical studies on these targets. Thereafter, we also discuss the challenges related to CAR-T therapy for AML and some promising strategies for overcoming these challenges, including novel approaches such as gene editing and advances in CAR design.
Recent advances in CAR-T therapy for acute myeloid leukemia Acute myeloid leukemia (AML) remains a clinical challenge despite the advent of chimeric receptor T-cell (CAR-T) therapy, as there are obstacles hindering the application of CAR-T cells in AML. In this review, we discuss the results of current relevant clinical trials, existing treatment strategies for AML and recent advances in preclinical research to provide insight for overcoming the inefficacy of CAR-T therapy for AML.
